Related Experiment Video

Updated: Jun 10, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

Receptor tyrosine kinases as therapeutic targets in cancer

Nancy E Hynes1

  • 1Friedrich Miescher Institute for Biomedical Research, Maulbeerstrasse 66, CH-4059 Basel, Switzerland.

Discovery Medicine
|August 14, 2010
PubMed

Insights

Erythroblastosis group B (ERBB) receptor tyrosine kinases are key proteins in cell signaling. Aberrant activation of these ERBB receptors drives human tumor development, making them important therapeutic targets.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Oncology

Background:

  • Receptor tyrosine kinases (RTKs) are cell surface proteins crucial for signal transduction.
  • ERBB receptors, a subgroup of RTKs, possess extracellular ligand-binding domains and intracellular kinase activity.
  • These receptors activate intracellular signaling pathways upon ligand binding and dimerization.

Purpose of the Study:

  • To review the role of ERBB receptor tyrosine kinases in human cancer.
  • To highlight ERBB receptors as significant therapeutic targets in oncology.
  • To discuss the development of ERBB-targeted inhibitors.

Main Methods:

  • Literature review focusing on ERBB receptor tyrosine kinases.
  • Analysis of the structure and function of ERBB receptors.
  • Examination of the aberrant activation of ERBB in human tumors.
  • Overview of current therapeutic strategies targeting ERBB.

Main Results:

  • ERBB receptor tyrosine kinases are frequently hyperactivated in various human cancers.
  • This aberrant activation contributes significantly to tumorigenesis and cancer progression.
  • Targeted inhibitors against ERBB receptors have shown clinical efficacy.

Conclusions:

  • ERBB receptor tyrosine kinases play a critical role in cancer biology.
  • Understanding ERBB signaling is vital for developing effective cancer therapies.
  • Targeted inhibition of ERBB receptors represents a successful therapeutic strategy in oncology.

More Related Videos

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

Related Concept Videos

Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Enzyme-linked Receptors01:00

Enzyme-linked Receptors

Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...